A new wave of biotech companies is lining up for public-market debut as IPO conditions appear to improve, according to recent dealflow notes. Braveheart Bio filed for a Nasdaq debut, positioning BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, as the flagship asset after encouraging Phase 2 readouts. Separate reporting highlights Jasper Therapeutics’ path back to capital markets via a merger with Kira Pharmaceuticals, a transaction designed to help Jasper recover from setbacks and fund a renewed pipeline. Together, the stories show how sponsors are using M&A and listings to re-open pathways to clinical capital and regulatory execution.